TY - T1 - Different responses of colorectal cancer cells to alternative sequences of cetuximab and oxaliplatin SN - / UR - http://hdl.handle.net/10138/277463 T3 - A1 - Narvi, Elli; Vaparanta, Katri; Karrila, Anna; Chakroborty, Deepankar; Knuutila, Sakari; Pulliainen, Arto; Sundvall, Maria; Elenius, Klaus A2 - PB - Y1 - 2018 LA - eng AB - Therapeutic protocols including EGFR antibodies in the context of oxaliplatin-based regimens have variable clinical effect in colorectal cancer. Here, we tested the effect of the EGFR antibody cetuximab in different sequential combinations with oxaliplatin on the growth of colorectal cancer cells in vitro and in vivo. Cetuximab reduced the efficacy of oxaliplatin when administered before oxaliplatin but provided additive effect when administered after oxaliplatin regardless of the KRAS or BRAF m... VO - IS - SP - OP - KW - ANTICANCER DRUGS; INHIBITORS; STAT3; CHEMOTHERAPY; COMBINATION; GEFITINIB; THERAPY; ACTIVATION; RESISTANCE; APOPTOSIS; 3111 Biomedicine; 3122 Cancers N1 - PP - ER -